The major risk factors for hepatocellular carcinoma (HCC) in contemporary clinical practice
are becoming increasingly related to sustained virological response after hepatitis C …

Portal vein tumour thrombosis is common among patients with advanced hepatocellular
carcinoma. Tremendous differences exist in the management of hepatocellular carcinoma …

Treatment allocation is extremely complex in patients with hepatocellular carcinoma (HCC)
because this neoplasm arises, in most cases, in patients with cirrhosis and additional …

Background and aims Epidemiology of hepatocellular carcinoma (HCC) is changing in most
areas of the world. This study aimed at updating the changing scenario of aetiology, clinical …

Portal vein involvement is considered one of the most fearful complications of hepatocellular
carcinoma (HCC). Portal vein tumor thrombosis (PVTT) is associated with aggressive tumor …

Objective: The aim of the study was to compare SURG vs SOR regarding the OS and
progression-free survival (PFS) in a real-world clinical scenario. Background data: The …

Abstract Background: The Barcelona Clinic Liver Cancer (BCLC) intermediate and
advanced stages (BCLC B and C) of hepatocellular carcinoma (HCC) both include …

Transcription factor E26 transformation specific sequence 1 (ETS-1) is a primary regulator in
the metastasis of human cancer cells, especially hepatocellular carcinoma (HCC) cells; and …

Hepatocellular carcinoma (HCC) is one of the major causes of morbidity, mortality, and
healthcare expenditure in patients with chronic liver disease in India. The Indian National …

Hepatocellular carcinoma (HCC) is a common complication in patients with chronic liver
disease and leads to significant morbidity and mortality. Liver disease and liver cancer are …